IHS Chemical Week

EnviroTech :: Regulatory :: Regulatory: Legal

FDA Issues Warning Letter to Lonza Plant in U.S.

1:21 AM MDT | September 14, 2011 | Deepti Ramesh

The U.S. Food and Drug Administration (FDA) issued a warning letter earlier this month to Lonza’s manufacturing plant at Hopkinton, MA, for deviating from current good manufacturing practice (cGMP). An FDA inspection from April 4, 2011 to May 6, 2011 at Lonza’s pharmaceutical and active pharmaceutical ingredient (API) manufacturing facility at Hopkinton identified significant violations of cGMP regulations for finished pharmaceuticals, and from cGMP for the manufacture of APIs, FDA says. Lonza responded on May 26, 2011 and the FDA says it has reviewed...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa